Aqemia is a next-gen pharmatech company generating one of the world’s fastest-growing drug discovery pipeline. Our mission is to find a massive number of drug candidates that will become the treatments of tomorrow. Central to our mission are our unique quantum and statistical mechanics algorithms we fuel into an artificial intelligence to design optimized molecules at scale.
Unlike usual AI-based platforms that need experimental data to train on, Aqemia tackles drug discovery projects from their earliest stage by generating its own data with quantum and statistical physics calculations. This major breakthrough makes it possible to push the limits of pharmaceutical R&D and discover therapeutic molecules more rapidly and with a better chance of success. We are a next-gen pharmatech company, massively scaling drug discovery projects.
Unlike usual AI-based platforms that need experimental data to train on, Aqemia tackles drug discovery projects from their earliest stage by generating its own data with quantum and statistical physics calculations. This major breakthrough makes it possible to push the limits of pharmaceutical R&D and discover therapeutic molecules more rapidly and with a better chance of success. We are a next-gen pharmatech company, massively scaling drug discovery projects.
Location: France, Ile-de-France
Employees: 11-50
Total raised: $170.73M
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | Agoranov | agoranov.c... |
| 27.03.2021 | Elaia Part... | elaia.com |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 01.04.2025 | Grant | $7.57M | - |
| 13.12.2024 | - | $99.94M | - |
| 30.01.2024 | Series A | $32.53M | - |
| 24.10.2022 | Series A | $29.58M | - |
| 17.10.2019 | Pre-Seed | $1.11M | - |
Mentions in press and media 22
| Date | Title | Description |
| 14.03.2026 | Elaia Fuels Europe's Deep Tech Future with €134M Fund | Elaia has closed its €134 million DTS3 fund. This deep tech seed fund targets European B2B startups. It doubles prior deep tech allocations. Elaia partners with top research institutions. The fund invests €1M-€13M in early-stage ventures. F... |
| 12.03.2026 | Elaia closes third DeepTech Seed fund at €134 million as “European DeepTech is reaching escape velocity” | Paris-based VC firm Elaia has announced the closing of its third DeepTech Seed fund (DTS3) at €134 million, which is double the size of its previous DeepTech Seed funds. DTS3’s final closing includes support from longtime partners and new i... |
| 12.03.2026 | Elaia closes €134M fund DTS3 to back Europe’s next generation of breakthrough startups | Elaia has closed its third deep tech seed fund (DTS3) at €134 million, double the size of its previous deep tech seed funds. The fund is developed in partnership with leading European research institutions, including PSL, INRIA, CNRS, the B... |
| 09.12.2025 | Aqemia to Attend the 44th Annual J.P. Morgan Healthcare Conference 2026 | Aqemia, a drug invention company combining generative AI and quantum-inspired physics, announces it will attend and hold 1×1 meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place at The Westin St. Francis in San Franci... |
| 27.05.2025 | Cathay Innovation: $1 Billion VC Fund Closed | Cathay Innovation announced today the final close of its latest venture capital fund at $1 billion, making it the largest AI-focused fund in the European Union. The closing of this fund marks a significant shift in AI-era venture capital, w... |
| 03.04.2025 | VIVATECH 2025 EXPLORES THE NEW FRONTIERS OF INNOVATION | PARIS, April 3, 2025 /PRNewswire/ -- The 9th edition of VivaTech, Europe's largest startup and tech event, will take place in Paris Porte de Versailles from 11 to 14 June 2025. VivaTech 2025 Press Conference SPANNING A DECADE OF TECHNOLOGIC... |
| 01.04.2025 | Aqemia's $7.4 Million Grant: A Leap into RNA Drug Discovery | Aqemia, a biotech company, is on the brink of a breakthrough. With a fresh $7.4 million grant from the France 2030 initiative, it aims to revolutionize drug discovery. This funding is not just a financial boost; it’s a ticket to uncharted t... |
| 01.04.2025 | Aqemia: $7.4 Million Grant Secured To Advance Epitranscriptomics Programs | Aqemia announced it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Creating on successes in epitranscriptomics, Aqemia looks to develop novel small-molecule drugs aga... |
| 01.04.2025 | Biotech Aqemia secures €7M grant for drug discovery using deep physics | Biotech Aqemia has received a $7.4M grant to expand and and accelerate of its computational platform to target RNA therapeutics, marking a significant step in the company’s broader mission to innovate drug discovery using generative AI. The... |
| 13.12.2024 | AQEMIA: Drug Discovery Pipeline Company Raises $38 Million | AQEMIA, a biotechnology company that teaches atomic-scale physics to a generative AI (GenAI) for inventing new medicines, announced two significant milestones: $100 million in total funding and the beginning of a global expansion, starting ... |
Show more